SI-BONE, Inc. - 1781346 - SI-BONE INC

Financial Performance:

• Revenue growth is driven by both surgeon-led SI joint dysfunction procedures and a strategic shift to interventional spine physicians in ASCs and in-office settings.
• Gross margins have remained stable at approximately 79.3%, with new product launches temporarily diluting margins to ~78% before optimization strategies aim to restore levels near 80%.
• Productivity per sales representative has increased to $2.3 million, up from less than $1.4 million four years ago, supporting the transition to positive EBITDA and cash flow break-even.
• The business operates with an asset-light model, maintaining industry-leading efficiency through hybrid sales forces that combine direct sales with case coverage agents.
• New DRGs effective October 1st are expected to provide reimbursement increases between $20,000 and $50,000 for complex pelvic fixation cases, removing cost barriers and allowing for higher implant usage per case.

Guidance and Future Outlook:

• Management has declined to provide specific 2027 financial guidance, citing the need to observe the performance of new reimbursement tailwinds in Q4 and Q1 2028.
• The company is on an "innovation super cycle" with a target of launching one to two new products annually, each targeting a new Significant Addressable Market (SAM).
• Outlook for 2027–2029 is described as highly positive, fueled by permanent reimbursement changes (new DRGs), in-office code expansion, and the launch of the Onyx platform.
• Long-term goals focus on expanding the "compromised bone" franchise beyond the pelvis, leveraging core competencies in low-density bone fixation to own new market segments.
• Revenue growth is expected to be driven by the inflection of multiple durable tailwinds, including NTAP eligibility for Onyx (effective Q4 2027) and the expansion of SI joint dysfunction into interventional spaces.

Business Segments and Product Lines:

• Onyx: The primary new launch, a platform for Upper and Lower Instrumented Vertebra (UIV/LIV) fixation to address ~27% failure rates in osteoporotic or complex fusion cases; estimated SAM of 200,000 procedures annually ($12k per case for deformity, $6k for degenerative).
• Granite: Already established as a standard of care in complex pelvic fusion, with clinical studies (Polar) showing revision rate reduction from 24% to 3%; serves as the commercial foundation for Onyx adoption.
• SI Joint Dysfunction: Remains the largest revenue contributor with a ~$280k TAM; growth is accelerating via interventional spine physicians using Allograft and Intra-TI platforms, supported by favorable CPT codes (27278, 27279).
• Trauma: Currently a single-solution business segment; managed via a collaboration with Smith & Nephew to optimize sales force focus on higher-growth areas while maintaining "green shoots" of growth.
• Commercial Infrastructure: Utilizes a hybrid sales model where agents support high-implant cases (e.g., Onyx) to free up direct sales reps for hunting and relationship building.

Market and Competitive Landscape:

• The company positions itself as a technology platform rather than a single-product entity, focusing on unmet clinical needs and high failure rates where competitors have not innovated.
• Onyx targets a "me-too" free environment by addressing specific failure points (UIV/LIV) in the spine fusion market, differentiating through clinical outcomes rather than incremental features.
• Market trends show a shift toward minimally invasive procedures performed by interventionalists in ASCs and in-office settings, which SibiOne is uniquely positioned to serve with its comprehensive platform.
• The "compromised bone" segment (osteoporosis/osteopenia) is identified as a major growth vector, expanding the addressable market beyond the pelvic fixation niche.

Risks and Challenges:

• Surgical Capacity Ramp: The speed of Onyx adoption depends on the ability to train surgeons and scale surgical capacity to match demand, a process requiring significant time.
• Reimbursement Timing: While NTAP provides long-term value, immediate adoption relies on existing commercial and DRG frameworks; any delays in hospital committee approvals could slow the initial ramp.
• Margin Dilution: New product launches initially introduce non-cash depreciation and lower margins, requiring rigorous supply chain optimization to maintain industry-leading gross margins.
• Patent Expirations: Investors are monitoring the expiration of the "triangle patent" (noted as expiring around 2026–2028), though management emphasizes the company's shift to a multi-product platform mitigates this risk.

Management Commentary and Tone:

• Tone is optimistic and confident, describing the business as being in an "innovation super cycle" with a flywheel effect from continuous product launches.
• Management emphasizes a disciplined, evidence-based approach, refusing to be a "me-too" company and prioritizing clinical data (e.g., upcoming Onyx clinical study) over aggressive marketing.
• CFO/CEO Savanchil (dual role) highlights strong operational discipline, noting that growth has been the primary driver of profitability improvements from negative EBITDA to cash flow break-even.
• Confidence is high regarding the durability of new reimbursement tailwinds, characterizing them as permanent and structural changes rather than temporary anomalies.

Analyst Questions and Answers:

• Onyx Adoption: Clarified that Onyx is being tested in three phases: Granite users, non-Granite spine surgeons, and surgeons who do not go to the pelvis; early alpha data shows success across all three groups.
• Reimbursement Impact: Confirmed that Onyx demand is clinically driven first, with reimbursement (DRGs/NTAP) acting as a facilitator; 60% of Granite volume was commercial prior to NTAP, suggesting similar independence for Onyx.
• Sales Force Health: Described as the "best in the industry," focusing on education and evidence; the Smith & Nephew collaboration was explicitly designed to prevent distraction from core growth engines.
• 2027 vs. 2026 Growth: Acknowledged potential for 2027 to outperform 2026 due to the convergence of new DRGs, Onyx launch, and interventional growth, though specific numbers are withheld until Q4 performance is clear.
• ROI on Sales Reps: Explained that the hybrid model increases productivity by ensuring reps are in the OR for high-value cases while using agents for case coverage, freeing up time for business development.

Other Key Points:

• The company has filed for NTAP status for Onyx, expected to be effective October 1, 2027, reinforcing the long-term economic viability of the product.
• Clinical evidence remains a core differentiator; management cited a 2-year study for Granite showing a revision rate drop from 24% to 3% and plans to launch a similar study for Onyx soon.
• The "compromised bone" strategy has successfully broadened the company's aperture, moving from a pelvic-specific franchise to a multi-call point technology platform.
• Management reiterated a focus on "one step at a time," prioritizing operational execution in Q4 and Q1 before committing to long-term financial targets.
• The narrative has shifted externally from viewing the company as a single-product entity to a scalable infrastructure capable of sustained innovation and market disruption.